Undecimal Bio launches with $18 million oversubscribed seed financing to address ‘liver trap’ in siRNA therapeutic delivery
Undecimal Bio, a platform biotechnology company advancing targeted delivery of siRNA therapeutics, today announced an oversubscribed $18 million USD seed financing.
Read original article on The Medical News →Related news
-
Triple-action drug retatrutide delivers major weight loss for people with diabetes, Phase III trial finds
United Kingdom
-
Technology-assisted approach can help prevent summer weight gain in adolescents
United Kingdom
-
Why managing vibration is critical in IVF
United Kingdom
-
Neck stiffness puts pitchers at risk of throwing-related injuries
United Kingdom
-
AI tool reveals what attracts immune cells to tumors and what keeps them away
United Kingdom
-
New research shows reduced toxicant exposure reduces biological activity
United Kingdom
-
AI screening helps more people with diabetes access sight-saving eye care
United Kingdom
-
Exposure to 'safer' plastic additive during pregnancy linked to smaller birth size
United Kingdom